Professor David Lalloo has been LSTM’s Director since 1 January 2019.
David Lalloo is a clinical academic in Tropical Medicine and Infectious Diseases with a a particular interest in clinical trials and epidemiological studies in LMICs. Having undergone initial training in Newcastle upon Tyne, David trained in General (Internal) Medicine, Infectious Diseases and Tropical Medicine, spending three years in Papua New Guinea. He undertook clinical and laboratory research in Oxford before moving as Senior Lecturer to the Liverpool School of Tropical Medicine in 1999. Prior to taking up the Directorship of LSTM in January 2019, David was Dean of Clinical Sciences and International Public Health and was Director of the Wellcome Trust Liverpool Glasgow Centre for Global Health Research and the Liverpool Wellcome Trust Clinical PhD Programme. He holds an appointment as an Honorary Consultant at the Royal Liverpool University Hospital and remains clinically active.
His research has focused particularly on HIV related infections, malaria and envenoming and he has also worked on COVID. He has active collaborations in a number of countries including Malawi, Uganda, Sri Lanka, Vietnam, Kenya, Nigeria, eSwatini, Ghana, Sierra Leone and South Africa. He has worked with the MLW Programme in Malawi for over twenty years and has a strong interest in identifying and supporting young UK and African clinicians interested in tropical research and strengthening scientific capacity in resource poor settings.
David has held a number of national roles. He chaired the DHSC COVID-19 Prophylaxis Oversight group and was an advisor to a number of DHSC, FCDO/DfID, NIHR and NICE COVID-19 groups. He currently chairs the NIHR Global Health Advisory Group, has been a member of the Medical Research Council Global Health group for over 10 years and was previously a member of SAGE for Ebola and Zika. He chaired the PHE Advisory Committee on Malaria from 2010-2019. He has sat on multiple funding committees and was Chair of the Wellcome Trust/ MRC/ DfID/DH Clinical Trials PaneI from 2016-2019.